The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania

Published Online:https://doi.org/10.1176/ajp.152.8.1192

OBJECTIVE: The authors' objective was to determine the efficacy of fluoxetine at high doses for the treatment of trichotillomania in a long-term, double-blind, placebo-controlled crossover trial. METHOD: Twenty-three adult chronic hair pullers agreed to take part in the trial, taking fluoxetine doses of up to 80 mg/day. The 31-week trial consisted of a 2-week washout phase, a first treatment phase of 12 weeks, a 5-week washout phase, and a crossover second treatment phase of 12 weeks. Sixteen patients (14 women and two men) completed the trial. RESULTS: There were no significant differences between fluoxetine and placebo treatments for the measures of weekly severity of hair pulling, weekly severity of urge to pull, daily hair counts (or estimated hair pulled), or days of hair pulling. CONCLUSIONS: The efficacy of fluoxetine in the treatment of trichotillomania was not demonstrated in this study.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.